eFFECTOR Therapeutics, Inc.
Clinical Trials
9
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Intravenous Zotatifin in Adults With Mild or Moderate COVID-19
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- Effector Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT04632381
- Locations
- 🇺🇸
Pinnacle Research Group, Anniston, Alabama, United States
🇺🇸Cullman Clinical Trials, Cullman, Alabama, United States
🇺🇸Tampa General Hospital, Tampa, Florida, United States
Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Effector Therapeutics
- Target Recruit Count
- 68
- Registration Number
- NCT04622007
- Locations
- 🇺🇸
Southern Cancer Center, Daphne, Alabama, United States
🇺🇸Southern Cancer Center, PC (Mobile Infirmary Circle), Mobile, Alabama, United States
🇺🇸Southern Cancer Center, PC (Airport Blvd), Mobile, Alabama, United States
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
- Conditions
- Solid Tumor, Adult
- Interventions
- First Posted Date
- 2019-09-17
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Effector Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT04092673
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Effector Therapeutics
- Target Recruit Count
- 16
- Registration Number
- NCT03690141
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Kimmel Center at Johns Hopkins, Baltimore, Maryland, United States
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- Effector Therapeutics
- Target Recruit Count
- 39
- Registration Number
- NCT03616834
- Locations
- 🇺🇸
University of Arizona - Cancer Center, Tucson, Arizona, United States
🇺🇸Pacific Shores Medical Group, Long Beach, California, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Los Angeles, California, United States
- Prev
- 1
- 2
- Next